French Venture Studio M2care Raises €26 Million Funding

Existing backers Mérieux Développement, Institut NAOS, Crédit Agricole Centre-Est, and Family Offices also participated. The capital will support eight new healthcare projects.

Florence Thueux, President of M2care, said: “I am delighted that France 2030’s French Tech Acceleration 2 fund has invested in our studio. Bpifrance is a leading player whose strong support will help to bring healthcare innovations to patients and into the market. I would like to sincerely thank Pierre Gillet, Océane Fleury, and the Bpifrance team for the trust they have placed in us.”

Founded in 2017 by Mérieux Développement and CEA Investissement, M2care is a HealthTech venture studio that creates, develops, and finances early-stage projects alongside their founders.

Read Also - Italian Social Platform Waveful Raises €1.8 Million In Pre-Seed Round

Acting as a bridge between academics, investors, and industry, M2care leverages its operational expertise, international network, and tailored ecosystems to turn lab-born ideas into market-ready health products that improve public health.

The studio has already invested in three ventures: Previa Medical, which offers a digital device to predict and prevent hospital emergencies; TheraSonic, developing ultrasound-based treatments for brain diseases; and Rhovica Neuroimaging, creating a sensor-equipped ventricular drainage catheter for patients at risk of elevated intracranial pressure.

M2care is actively advancing projects in cardiology, dermatology, ophthalmology, and neurology, and is preparing to launch its fourth project.

Carsten Laue, General Manager of M2care, added: “We are very pleased that France 2030’s FTA 2 fund managed on behalf of the French government by Bpifrance is supporting our venture studio and helping to create pioneering HealthTech startups.”

The French Tech Acceleration 2 (FTA2) fund, with €100M in funding, was launched under the Programme d’Investissements d’Avenir (PIA) and is now part of France 2030. Designed to support startup accelerators, studios, and related structures, FTA2 is investing in M2care to drive healthcare innovation and speed the transfer of lab-developed technologies to market. This funding will enable M2care to create and develop eight new healthcare projects, benefiting patients and public health.

Pierre Gillet, Investment Director at Bpifrance, concluded: “By investing in M2care, we are reaffirming our commitment to strengthening our technological sovereignty in healthcare. We are delighted to contribute to this effort on behalf of the French government.”

About M2care

M2care is a HealthTech venture studio that partners with founders to create, develop, and fund early-stage healthcare projects. Bridging academia, investors, and industry, M2care transforms lab-born ideas into market-ready health products. It focuses on cardiology, dermatology, ophthalmology and neurology, aiming to improve public health and patient outcomes.